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associated with HPV infection. Our recent report has shown that high-
risk HPV 16/18 infections were associated with female lung cancer 
incidences in Taiwan. To address the correlation between the different 
p53 genotypes, HPV infection and HPV oncoprotein expression in p53 
protein degradation of lung cancer, 60 health subjects and 141 primary 
lung cancer patients were included in this study. PCR-RFLP, nested-
PCR and immunohistochemial analysis were used to detect the p53 
codon 72 polymorphism, HPV 16/18 infection, HPV 16/18 E6 and p53 
protein expression. Immunohistochemistry data showed that HPV 16 or 
18 E6 protein was more frequently detected in female, adenocarcinoma, 
and nonsmoking lung tumors, compared with that of male, squamous 
cell carcinoma, and smoking lung tumors. Interestingly, HPV 16/18 E6 
expressions but not HPV 16/18 DNA were reversely correlated with 
p53 expression, which was further conﬁrmed by tissue in situ immu-
nostaining. Additionally, the frequency of p53 protein degradation in 
HPV 16/18 E6-positive/Arg homozygosity lung cancer tumors is much 
higher than that in the other three categorizes. This correlation was not 
found in HPV DNA infection. In conclusion, HPV 16/18 E6 proteins 
involvement in p53 inactivation to contribute to HPV-infected lung 
tumorigenesis is correlate with p53 genotypes.
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High resolution melting analysis for rapid and sensitive EGFR 
mutation detection
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High Resolution Melting (HRM) analysis is an emergent technique that 
has enormous potential for the detection of DNA sequence changes. 
New instruments combined with next generation DNA intercalating 
dyes allow the discrimination of single base changes in PCR-ampli-
ﬁed products. The technology shows great promise for the detection of 
somatic mutations in clinical samples.
Clinical tumour samples present particular difﬁculties as the actual pro-
portion of tumour cells is highly variable and in many cases sequencing 
is not sufﬁciently sensitive to pick up the mutations. We developed as-
says to detect somatic gene mutations in exons 18-21 of the EGFR gene 
using HRM analysis. We also used assays for exon 2 of the KRAS gene 
and exon 20 of the HER2 gene. We validated these assays in a panel 
of 300 previously sequenced lung cancer biopsies. Sensitivity testing 
showed that the HRM assay was able to detect as little as 5% mutant 
sequence in a background of wild type DNA. HRM was able to readily 
detect sequence variation that was barely visible by sequencing leading 
to a lower rate of false negative results. These results demonstrate the 
utility of HRM analysis for the detection of somatic mutations in clini-
cal samples and for pre-screening of samples prior to sequencing. 
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Activated coagulation factors in human malignant effusions from 
patients with lung carcinoma
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We have shown that the thrombin Protease Activated Receptors PAR-1 
are expressed in primary cancer cells isolated from peritoneal and pleu-
ral malignant effusions (Oncogene 2005, 24: 8240-51). Here, our main 
goal was to evaluate several coagulation and thrombin activation ef-
fectors and markers in a series of 15 malignant effusions from patients 
with lung carcinomas (NSCLC, 11; SCLC, 4). All patients present a 
highly activated coagulation system in blood and their malignant effu-
sions, as indicated by high levels of prothrombin F1.2 fragments and 
D-dimers. Notably, we detected in the effusions all the coagulation fac-
tors of the tissue factor pathway inducing thrombin activation, namely 
factors FVII, FV, FX and FII, as well as high VEGF levels and IGF-II 
in mature and precursor forms. Fibrin clot formation also correlated 
with higher levels of free ionized calcium (iCa), suggesting that iCa 
and its binding protein albumin are regulatory factors for ﬁbrinogen-
esis in effusions. Consequently, thrombin, VEGF and IGF-II appear to 
converge in the promotion of survival and invasivity of the metastatic 
cancer cells from blood to the malignant effusions. Thus, we add new 
insights on the interconnections between blood coagulation disorders 
in cancer patients and thrombin activation in malignant effusions, 
including their functional interaction with PAR in metastatic cancer 
cells. Based upon these data we propose to counteract the metastatic 
cascades by targeted interaction with the coagulation system. Pos-
sible therapeutic approaches would be by the application of thrombin 
inhibitors, VEGF-directed antibodies, drugs targeting the VEGF and 
thrombin PAR signaling pathways such as thyrosin kinase or G-protein 
inhibitors. 
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Chromosomal Changes In Lung Cancer
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Kidwai Memorial Institute of Oncology, Bangalore, India
Lung Cancer is a major chest problem in our society. It may present 
as a mass, pleural effusion, superior vena caval syndrome or a MUO 
(Metastasis of unknown origin). This study was carried out to analyze 
chromosomal patterns in lung cancer and assess its role as a diagnostic 
aid in certain clinical situations. 
25 patients entered the study. All underwent a detailed work up for 
the primary and metastatic lesions. Tissue samples were obtained by 
transthoracic ultrasound guided ﬁne needle aspiration (FNA)/ 18 of 
these were from the primary site the lung, 5 from metastatic nodes and 
1 from a pleural aspirate, 1 from pulmonary metastasis. The samples 
were processed directly in overnight / 24 hours cultures. Cell division 
was arrested at metaphase with colchicine (Boehringer 50ml of 100 ug 
/ ml) and analyzed after GTG banding (ISCN 1991). 
Metaphases were recovered in 14/25 patients. Cell poor aspirates were 
the reason for culture failures in the remainder. Of the 14 successful 
cultures, 9 were from the lung 8 NSCLC and 1 SCLC) and 3 from 
metastatic nodes (one small cell carcinoma and one poorly differentia-
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tion carcinoma) 1 each from pulmonary metastasis and pleural ﬂuid. 
All showed several chromosomal abnormalities. With the modal 
number varying between 56 - 87 chromosomes. The consistent ﬁnding 
in 9/10 cases was a deletion of 3p while 1 had a translocation involving 
chromosome 3. 
In this study tumors irrespective of being a NSCLC or SCLC showed 
that chromosome 3 was consistently involve hinting that this cytoge-
netic proﬁle could evolve as a new diagnostic tool in difﬁcult clinical 
situations. 
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molecules in human non-small cell lung cancer
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Background: Down-regulation or loss of human leukocyte antigen 
(HLA) class I has been reported in various malignancies in associa-
tion with poor patient survival. These ﬁndings may reﬂect an escape 
of tumor cells losing intact HLA class I molecules from HLA class 
I-restricted, tumor-associated antigen-speciﬁc cytotoxic T lymphocytes 
in recognition as well as in destruction. However, clinical impact of the 
down-regulation or loss of HLA class I in patients with non-small cell 
lung cancer (NSCLC) is still unknown. In the present study, we inves-
tigated clinical signiﬁcance of alteration in expression of HLA class I 
molecules in surgically resected NSCLC using tissue array analysis.
Method: Formalin-ﬁxed parafﬁn-embedded sections were obtained 
from 105 NSCLC (60 adenocarcinoma, 37 squamous cell carcinoma, 
and 6 large cell carcinoma). HLA class I and β2- microglobulin expres-
sion were analyzed using tissue array analysis. Imuunohistochemical 
study was performed using anti-HLA class I mAb EMR8-5 and anti-
β2- microglobulin mAb BBM1/sc-13565. Correlation between HLA 
class I or β2- microglobulin expression and clinicopathological param-
eter was analyzed statistically. Additionally, survival analysis was also 
performed using Kaplan-Meier’s method.
Result: There was no signiﬁcant correlation between HLA class I 
and clinicopathological parameters. On the other hand, signiﬁcant 
correlations were observed between β2- microglobulin expression 
and tumor size(p=0.0003), histological subtype(p=0.0285), nodal 
status(p=0.0335),and pathological stage(p=0.0335). Loss of β2- mi-
croglobulin expression was correlated with poor patient survival 
(p=0.0121), although HLA class I was not(p=0.8243).
Conclusion: Although clinical impact of HLA alteration was still 
unclear, β2- microglobulin expression might be involved in cancer 
progression in human NSCLC possibly through aberration of several 
molecules which contains β2- microglobulin.
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Purpose: To assess the activation patterns of RTK pathways, i.e. pro-
tein kinase B (PKB/Akt) and mitogen activated protein kinase (MAPK) 
pathways, in lung adenocarcinoma as compared with clinico-pathologi-
cal factors and status of EGFR and KRAS mutations. 
Experimental Design: 99 evaluable cases with primary lung adenocar-
cinomas surgically resected between 1998 and 1999 were selected for 
this study. Akt and MAPK phosphorylation (pAkt and pMAPK) was 
examined by means of immunohistochemistry. We deﬁned that cases 
with pAkt+/pMAPK- immunoreactivity to be the “Akt pathway type” 
and the pAkt-/pMAPK+ pattern to be the “MAPK pathway type.” Both 
positive and negative controls were prepared using mouse xenografts 
of PC-3 (pAkt+/MAPK-) and HTB26 (pAkt-/pMAPK+) cell lines. 
Univariate and multivariate analysis were performed to evaluate the 
association of these downstream mainly activated pathways and clinical 
signiﬁcance. The mutational status of EGFR and KRAS was deter-
mined by direct sequencing.
Results: Of the 99 cases, rates of the Akt pathway type and the MAPK 
pathway type were 32% (n=32) and 29% (n=29), respectively. Cases 
with immunoreactivity to both of the antibodies were not included 
in either type. Mutation assay revealed EGFR mutations in 55 cases 
(55%), and KRAS mutation in 7 cases (7%). The predictive factors for 
the MAPK pathway type were cumulative smoking and KRAS muta-
tion by univariate analysis. As all the cases with KRAS mutations were 
strongly positive for pMAPK, KRAS mutation status was mostly a 
highly predictive factor for the Akt pathway type.
Conclusions: Association between Ras/MAPK pathways activa-
tion and KRAS mutations was conﬁrmed in tumor specimens of lung 
adenocarcinoma. The MAPK pathway type was statistically associated 
also with cumulataive smoking. 
P3-007 BSTB: Molecular Pathology Posters, Wed, Sept 5 – Thur, Sept 6 
Relationship between expression of ERCC1and estrogen receptor 
in patients with adenocarcinoma of the lung
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Background: The incidence of lung adenocarcinoma in Korea is 
increasing recently. Estrogen and EGFR pathway may be important in 
lung cancer carcinogenesis. This study was conducted to investigate the 
relationship among expression rate of estrogen receptor(ER), ERCC1, 
Kras and EGFR mutation in adenocarcinoma of the lung.
Material and Method: We performed the retrospective review of 
clinical information that diagnosed as adenocarcinoma of lung at Kosin 
University Gospel Hospital, Busan, South Korea from January 1999 to 
September 2005. Patient’s demographics, stage, serum tumor markers, 
pathologic classiﬁcation were analyzed. EGFR mutations in exons: 18, 
19, 20, 21, and K-ras mutation in exon 12, 13 were analyzed by DNA 
sequencing. The prevalence of ERα, ERβ, and ERCC1 were assessed 
by standard immuonohistochemical (IHC) methods using formalin-
ﬁxed, parafﬁn-embeded tumor specimens. 
Results: For all 84 patients with adenocarcinoma (stage IA in 10, IB 
22, IIA 6, IIB 7, IIIA 25, IIIB 7, and IV 7), 43 (51.2%) were male, 41 
(48.8%) female, and mean age was 57 years old. Mutations of EGFR 
mutations and KRAS were present in 25.7%, 9.5% of samples, respec-
tively. In IHC stain, ER expression was 65.5%, ERα expression in 
41.7%, ERβ in 51.2%, and both expressions in 27.4%. The expression 
rate of ERCC1 was 31%. There were correlation between ER expres-
sion and ERCC1 expression especially in ERβ expression (p=0.000). 
However there was no correlation between ER expression and EFGR 
